rani therapeutics hldgs inc. - RANI
RANI
Close Chg Chg %
2.47 -0.12 -4.86%
Pre-Market
2.35
-0.12 (4.86%)
Volume: 700.68K
Last Updated:
Nov 14, 2024, 4:00 PM EDT
Company Overview: rani therapeutics hldgs inc. - RANI
RANI Key Data
| Open $2.42 | Day Range 2.26 - 2.47 |
| 52 Week Range 1.90 - 8.75 | Market Cap $79.76M |
| Shares Outstanding 32.29M | Public Float 21.82M |
| Beta 0.11 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.18 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 2.08M |
RANI Performance
| 1 Week | -2.49% | ||
| 1 Month | -12.31% | ||
| 3 Months | -15.77% | ||
| 1 Year | 16.92% | ||
| 5 Years | N/A |
RANI Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
8
Full Ratings ➔
About rani therapeutics hldgs inc. - RANI
Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company was founded by Mir Imran on February 21, 2012 and is headquartered in San Jose, CA.
RANI At a Glance
Rani Therapeutics Holdings, Inc.
2051 Ringwood Avenue
San Jose, California 95131
| Phone | 1-408-457-3700 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -33,970,000.00 | |
| Sector | Health Technology | Employees | 140 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
RANI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 6.718 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.20 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.384 |
RANI Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -242,642.857 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
RANI Liquidity
| Current Ratio | 6.327 |
| Quick Ratio | 6.327 |
| Cash Ratio | 6.138 |
RANI Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -40.942 |
| Return on Equity | -136.642 |
| Return on Total Capital | -79.064 |
| Return on Invested Capital | -65.698 |
RANI Capital Structure
| Total Debt to Total Equity | 233.942 |
| Total Debt to Total Capital | 70.055 |
| Total Debt to Total Assets | 51.97 |
| Long-Term Debt to Equity | 190.30 |
| Long-Term Debt to Total Capital | 56.986 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Rani Therapeutics Hldgs Inc. - RANI
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | - | 462.00K | 2.72M | - |
Sales Growth
| - | -52.81% | +488.10% | -100.00% | |
Cost of Goods Sold (COGS) incl D&A
| - | - | 1.31M | 822.00K | - |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 589.00K | 497.00K | 1.31M | 822.00K | |
Depreciation
| 589.00K | 497.00K | 1.31M | 822.00K | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | - | - | -37.35% | - |
Gross Income
| - | - | (1.31M) | (822.00K) | - |
Gross Income Growth
| - | - | - | +37.35% | - |
Gross Profit Margin
| - | - | - | - | - |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 16.42M | 53.82M | 62.14M | 65.28M | |
Research & Development
| 12.04M | 26.48M | 36.61M | 39.62M | |
Other SG&A
| 4.37M | 27.34M | 25.53M | 25.65M | |
SGA Growth
| -40.26% | +227.82% | +15.46% | +5.05% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 63.00K | 1.07M | - |
EBIT after Unusual Expense
| (16.61M) | (52.67M) | (63.45M) | (66.10M) | |
Non Operating Income/Expense
| 63.00K | 89.00K | 1.25M | 3.30M | |
Non-Operating Interest Income
| 63.00K | 89.00K | 1.25M | 3.30M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 124.00K | 466.00K | 1.07M | 5.08M | |
Interest Expense Growth
| +1,140.00% | +275.81% | +129.83% | +374.79% | |
Gross Interest Expense
| 124.00K | 466.00K | 1.07M | 5.08M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (16.67M) | (53.05M) | (63.27M) | (67.88M) | |
Pretax Income Growth
| +37.31% | -218.26% | -19.28% | -7.28% | |
Pretax Margin
| - | - | -3,607.79% | -1,952.41% | - |
Income Tax
| - | 35.00K | 41.00K | 70.00K | |
Income Tax - Current - Domestic
| - | 35.00K | 41.00K | 70.00K | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (16.70M) | (53.09M) | (63.34M) | (67.88M) | |
Minority Interest Expense
| - | (44.76M) | (32.76M) | (33.91M) | |
Net Income
| (16.70M) | (8.33M) | (30.59M) | (33.97M) | |
Net Income Growth
| +37.18% | +50.12% | -267.16% | -11.06% | |
Net Margin Growth
| - | - | -3,615.37% | -306.62% | - |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (16.70M) | (8.33M) | (30.59M) | (33.97M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (16.70M) | (8.33M) | (30.59M) | (33.97M) | |
EPS (Basic)
| -0.8462 | -0.4226 | -1.2843 | -1.3319 | |
EPS (Basic) Growth
| +37.18% | +50.06% | -203.90% | -3.71% | |
Basic Shares Outstanding
| 19.74M | 19.71M | 23.82M | 25.50M | |
EPS (Diluted)
| -0.8462 | -0.4226 | -1.2843 | -1.3319 | |
EPS (Diluted) Growth
| +37.18% | +50.06% | -203.90% | -3.71% | |
Diluted Shares Outstanding
| 19.74M | 19.71M | 23.82M | 25.50M | |
EBITDA
| (15.96M) | (51.10M) | (62.14M) | (65.28M) | |
EBITDA Growth
| +39.79% | -220.29% | -21.60% | -5.05% | |
EBITDA Margin
| - | - | -3,453.46% | -1,880.82% | - |
Snapshot
| Average Recommendation | BUY | Average Target Price | 12.00 | |
| Number of Ratings | 8 | Current Quarters Estimate | -0.274 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | -1.222 | |
| Last Quarter’s Earnings | -0.24 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.33 | Next Fiscal Year Estimate | -1.027 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 2 | 9 | 9 |
| Mean Estimate | -0.27 | -0.41 | -1.22 | -1.03 |
| High Estimates | -0.17 | -0.21 | -0.90 | -0.59 |
| Low Estimate | -0.56 | -0.61 | -2.19 | -1.96 |
| Coefficient of Variance | -45.07 | -68.99 | -38.29 | -44.10 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 8 | 8 | 8 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Rani Therapeutics Hldgs Inc. - RANI
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Rani Therapeutics Hldgs Inc. - RANI
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 31, 2024 | Laureen DeBuono Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 31, 2024 | Jean-Luc Butel Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 31, 2024 | Dennis Arthur Ausiello Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 31, 2024 | Mir A. Imran Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 31, 2024 | Andrew Carl Farquharson Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 31, 2024 | Maulik K. Nanavaty Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 31, 2024 | Lisa Rometty Director | 50,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Dec 13, 2023 | South Cone Investments LP | 12,131,554 | Open market or private purchase of non-derivative security Non-derivative transaction at $2.01 per share | 24,384,423.54 |